Cytovance Biologics Inks $22.5M

Cytovance Biologics has closed on $22.5 million in growth capital from Greenwich, Conn.-based firm Great Point Partners. Cytovance, which is based in Oklahoma City, is a manufacturer of mammalian and microbial biologics for biotechnology and pharmaceutical customers. The new funding will help Cytovance to expand its manufacturing operations. As a result of the round, Great Point managing directors Jeffrey Jay and David Kroin, as well as senior vice president Noah Rhodes, will join Cytovance's board.

DealsNorth AmericaUSBriefs